Skip to main content
Kay Barnes on Muck Rack

Kay Barnes

As seen in: MDPI, American Society for Microbiology (ASM)
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work. Claim your profile

Get in touch with Kay

Contact Kay, search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack

Actions

Share this page

Is this you?

As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile

Articles

In Vitro Activity of Finafloxacin against Panels of Respiratory Pathogens

|
By Sarah Harding Verified, Kay Barnes, Stephen Hawser, Christine Bentley
| MDPI
Abstract : This study determined the in vitro activity of finafloxacin against panels of bacterial strains, representative of those associated with infection in cystic fibrosis patients and predominately isolated from clinical cases of respiratory disease. Many of these isolates were resistant to various antimicrobials evaluated including the aminoglycosides, cephalosporins, carbapenems and fluoroquinolones.
Open in Who Shared Issue with article?

The BALB/c Mouse Model for the Evaluation of Therapies to Treat Infections with Aerosolized Burkholderia pseudomallei

|
By Michelle Nelson, Kay Barnes, CHRISTOPHER COTE, Carwyn H. Davies
| MDPI
1. Melioidosis Burkholderia pseudomallei, the causative agent of the disease melioidosis, is a saprophytic bacterial pathogen living in soil and stagnant waters and is endemic to many parts of the world. It is naturally resistant to multiple antibiotics and the current treatment regime is lengthy, comprising two phases totaling 6–9 months of antibiotic intervention [1,2,3]. In addition, strains resistant to standard-of-care therapeutics are being reported [4,5,6,7]. The recent identification of B.
Open in Who Shared Issue with article?

Finafloxacin Is an Effective Treatment for Inhalational Tularemia and Plague in Mouse Models of Infection

|
By Kay Barnes, Mark Richards, Thomas Laws, Alejandro Nuñez
| American Society for Microbiology (ASM)
Experimental Therapeutics Kay B. Barnes, Mark I. Richards, Thomas R. Laws, Alejandro Núñez, Joanne E. Thwaite, Christine Bentley, Sarah V. Harding DOI: 10.1128/AAC.02294-20 ABSTRACT Infection with aerosolized Francisella tularensis or Yersinia pestis can lead to lethal disease in humans if treatment is not initiated promptly.
Open in Who Shared Issue with article?
See all 4 articles